Please login to the form below

Not currently logged in
Email:
Password:

Takeda appoints Christophe Weber as its new CEO

Frenchman had been widely expected to succeed Yasuchika Hasegawa

Takeda HQ Japanese pharma firm Takeda has promoted Christophe Weber, its former chief operating officer, to be president and chief executive officer of the firm.

This will become effective from April 1 this year. He will take over from the long-standing Yasuchika Hasegawa, who will become the new chairman of the board.

The firm says that Weber will also be the last person to fulfil the role of COO, as this position will no longer exist when he takes up the reins.

Weber, formerly of GlaxoSmithKline, said: “First, I would like to thank Yasuchika Hasegawa and the board of directors for their trust. I am honoured and thrilled with the role of CEO and determined to fulfil my duties. I will devote all my energy to leading the new Takeda organisation from April 1, 2015, and continue to make contributions to patients and healthcare professionals, to engage and motivate our employees, while responding to the expectations of investors and shareholders.”

Hasegawa added: “Since he became COO of the company last April, I have been supporting Christophe and at the same time carefully observing his performance as a CEO successor. I have concluded that he is ready to assume Takeda's CEO role, and therefore I have decided to appoint him CEO when the new organisational structure takes effect from April."

This also marks a cultural turning point for the Japanese company, which traditionally has promoted Japanese executives to top roles; Weber is the first non-native to take the CEO position at the company in its 200-year history.

Article by
Ben Adams

4th March 2015

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Redbow Consulting Group

Redbow Consulting Group is a specialist healthcare management consultancy specialising in business strategy and marketing...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...